Chemical industry – Page 78
-
-
Business
Review says cheaper drug is safe for eye disease
Cochrane collaboration says side effects of expensive Lucentis and off-label Avastin are similar
-
Business
Gilead licenses generic hepatitis C drug in India
Company aims to head off competition and grab a slice of royalties
-
BusinessBayer to sever polymer arm
German chemical giant’s exit from the materials world will help fund its crop and healthcare ambitions
-
Business
US drops restrictions on more GM seeds
Dow’s herbicide-resistant corn and soybeans spark renewed criticism from environmental campaigners
-
BusinessUS pushes for global phase-out of HFCs
Executive actions and industry commitments aim to speed up adoption of alternatives to hydrofluorocarbon greenhouse gases in refrigeration and air conditioning
-
BusinessFreeing a world of fixers
Company profile: Sugru mouldable silicone rubber lets you mend what’s broken and hack stuff better
-
Business
Eastman snaps up Taminco for $2.8bn
Purchase will strengthen Eastman in niche markets and offers cost savings
-
Business
Pharma sales ‘will reach $1 trillion’ in 2014
Report predicts continued growth as sales reach an all-time high
-
Business
Cipla targets asthma market with Advair copy
Indian pharma company Cipla has launched a generic version of GSK’s best selling drug
-
Business
Growth slow for European chemicals in 2014
Results for the first half held back by stagnant sales and production dips
-
BusinessBP faces $18bn fine over Deepwater
US judge rules that BP’s recklessness caused blowout through ‘gross negligence or willful misconduct’, but the firm will appeal
-
Business
Servier to appear in adverts over lack of transparency
Adverts in the medical press will name French pharma firm for failing to comply with disclosure rules
-
Business
Piramal exits drug discovery in India
Company will concentrate on generic medicines and clinical and contract research.
-
Business
Novo Nordisk quits inflammation R&D and cuts jobs
Firm will return to primary focus on diabetes and obesity
-
Business
Halliburton settles Deepwater Horizon claims
Company will pay $1.1bn for damage to property and commercial fishing
-
Business
Exelexis slashes workforce by 70%
Poor clinical trial performance pushes company into cost-cutting drive
-
BusinessRoche to buy InterMune for respiratory boost
$8.3bn deal gives Roche a leading position in pulmonary fibrosis
-
Business
DuPont settles pollution charges for $1.3m
Allegations relate to eight hazardous chemical leaks in West Virginia between 2006 and 2010
-
Business
Clinical collaborations drive cancer immunotherapy
Companies race to pair up chemotherapy drugs with immune system-boosting antibodies to greatest effect in trials